Logo image of ADMS

Adamas Pharmaceuticals Inc (ADMS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ADMS - Common Stock

8.22
+0.06 (+0.74%)
Last: 11/23/2021, 4:18:38 PM
8.3
+0.08 (+0.97%)
After Hours: 11/23/2021, 4:18:38 PM
Fundamental Rating

2

Taking everything into account, ADMS scores 2 out of 10 in our fundamental rating. ADMS was compared to 528 industry peers in the Biotechnology industry. ADMS may be in some trouble as it scores bad on both profitability and health. ADMS shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ADMS had negative earnings in the past year.
ADMS Yearly Net Income VS EBIT VS OCF VS FCFADMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 -20M -40M -60M -80M -100M

1.2 Ratios

Industry RankSector Rank
ROA -43.55%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADMS Yearly ROA, ROE, ROICADMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 2K 4K 6K 8K 10K

1.3 Margins

Industry RankSector Rank
OM -44.55%
PM (TTM) -71.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADMS Yearly Profit, Operating, Gross MarginsADMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 0 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ADMS has more shares outstanding
  • ADMS has a worse debt/assets ratio than last year.
ADMS Yearly Shares OutstandingADMS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 5M 10M 15M 20M 25M
ADMS Yearly Total Debt VS Total AssetsADMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -3.57, we must say that ADMS is in the distress zone and has some risk of bankruptcy.
  • A Debt/Equity ratio of -5.76 indicates that ADMS is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -5.76
Debt/FCF N/A
Altman-Z -3.57
ROIC/WACCN/A
WACCN/A
ADMS Yearly LT Debt VS Equity VS FCFADMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 4.53 indicates that ADMS has no problem at all paying its short term obligations.
  • ADMS has a Quick Ratio of 4.17. This indicates that ADMS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.53
Quick Ratio 4.17
ADMS Yearly Current Assets VS Current LiabilitesADMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

  • ADMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.84%, which is quite impressive.
  • Looking at the last year, ADMS shows a very strong growth in Revenue. The Revenue has grown by 26.34%.
  • The Revenue has been growing by 107.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.87%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y407.4%
Revenue growth 5Y107.84%
Sales Q2Q%28.33%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.28% on average over the next years. This is quite good.
  • Based on estimates for the next years, ADMS will show a very strong growth in Revenue. The Revenue will grow by 20.86% on average per year.
EPS Next Y48.66%
EPS Next 2Y34.88%
EPS Next 3Y24.11%
EPS Next 5Y12.28%
Revenue Next Year26.58%
Revenue Next 2Y29.99%
Revenue Next 3Y21.96%
Revenue Next 5Y20.86%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADMS Yearly Revenue VS EstimatesADMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ADMS Yearly EPS VS EstimatesADMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • ADMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ADMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADMS Price Earnings VS Forward Price EarningsADMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.88
ADMS Per share dataADMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ADMS's earnings are expected to grow with 24.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.88%
EPS Next 3Y24.11%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ADMS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Adamas Pharmaceuticals Inc

NASDAQ:ADMS (11/23/2021, 4:18:38 PM)

After market: 8.3 +0.08 (+0.97%)

8.22

+0.06 (+0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)03-01
Inst Owners0.22%
Inst Owner Change0%
Ins Owners4.9%
Ins Owner Change0%
Market Cap374.98M
Revenue(TTM)88.19M
Net Income(TTM)-62.70M
Analysts71.43
Price Target8.69 (5.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.25
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -10.88
EPS(TTM)-2.02
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.93
BVpS-0.47
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -44.55%
PM (TTM) -71.1%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity -5.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.53
Quick Ratio 4.17
Altman-Z -3.57
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.87%
EPS Next Y48.66%
EPS Next 2Y34.88%
EPS Next 3Y24.11%
EPS Next 5Y12.28%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y407.4%
Revenue growth 5Y107.84%
Sales Q2Q%28.33%
Revenue Next Year26.58%
Revenue Next 2Y29.99%
Revenue Next 3Y21.96%
Revenue Next 5Y20.86%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Adamas Pharmaceuticals Inc / ADMS FAQ

What is the fundamental rating for ADMS stock?

ChartMill assigns a fundamental rating of 4 / 10 to ADMS.


What is the valuation status for ADMS stock?

ChartMill assigns a valuation rating of 0 / 10 to Adamas Pharmaceuticals Inc (ADMS). This can be considered as Overvalued.


What is the profitability of ADMS stock?

Adamas Pharmaceuticals Inc (ADMS) has a profitability rating of 3 / 10.


What is the financial health of Adamas Pharmaceuticals Inc (ADMS) stock?

The financial health rating of Adamas Pharmaceuticals Inc (ADMS) is 4 / 10.